The Hyderabad-based Metrochem API Private Ltd, an integrated Active Pharmaceutical Ingredients (APIs), Pellets and Intermediates manufacturing company, is expecting to obtain WHO-GMP certification for its Bulk Pellets facility at Jeedimetla industrial area in Hyderabad, this year.

NV Rao, managing director of Metrochem said, the company is constantly improving its R&D capability and is currently catering to major bulk drugs manufacturers such as DRL, Cadila and Ranbaxy.

It manufactures APIs that include omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole and itracanozole meeting international standards and pellets including omeprazole, lansoprazole, rabeprazole, pantoprazole, itraconazole and domperidone. It also produces intermediate chemicals for the APIs that it develops.

In addition to Bulk Pellets facility, the company has API and intermediates manufacturing facilities at Jinnaram and Jeedimetla in and around Hyderabad. It has a centralized Research and Development centre at Hyderabad. It is an ISO 9001-2000 company.

The company hopes to obtain WHO-GMP accreditation for its API facilities in the coming years, which will enable to foray into overseas markets. The company is expecting a turnover of Rs 20 crore this financial year and is targeting to achieve Rs 35 crore in the next fiscal. In the coming two years, the company will take up forward and backward integration, he added.